ConductScience.org, home

Paper16044444

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Gertz MA and 12 others. Am J Hematol, 2005. Cited by 1,173 papers, by iCite.

Cite this record

ConductScience Library. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Papers, record 16044444. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16044444

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.
PubMed
Journal
Am J Hematol
PubMed
Year
2005
PubMed
Publication types
Consensus Statement, Journal Article, Review
PubMed
Citations, by iCite
1,173
iCite
Relative citation ratio, by iCite
31.3
iCite
Revised in PubMed
2026-01-28
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gertz MAMorie A
2Comenzo RRay
3Falk RHRodney H
4Fermand JPJean Paul
5Hazenberg BPBouke P
6Hawkins PNPhilip N
7Merlini GGiampaolo
8Moreau PPhilippe
9Ronco PPierre
10Sanchorawala VVaishali
11Sezer OOrhan
12Solomon AAlan
13Grateau GGiles

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AmyloidMajor topic
AmyloidosisMajor topic
Immunoglobulin Light ChainsMajor topic
France
Humans
Organ Specificity

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02245867Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL AmyloidosisBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by512

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,173 citations.

PMIDTitleJournalYearIn PapersSource
42894083Expanding role of nuclear medicine in cardiac amyloidosis: insights from the EJNMMI collection.EJNMMI Rep2026https://conductscience.org/library/papers/42894083PubMed
42855647Myocardial work in light-chain and transthyretin-related amyloidosis with preserved ejection fraction: a cardiovascular magnetic resonance study.Insights Imaging2026https://conductscience.org/library/papers/42855647PubMed
42780369
Sequential Autologous Stem Cell Transplantation and Ciltacabtagene Autoleucel for Concurrent Multiple Myeloma and Presumptive Immunoglobulin Heavy- and Light-Chain Amyloidosis in a Patient With Systemic Lupus Erythematosus.
Cureus2026https://conductscience.org/library/papers/42780369PubMed
42709342Amyloidosis & Advanced Heart Failure: When to Consider Cardiac Transplantation and What are the Results?Curr Heart Fail Rep2026https://conductscience.org/library/papers/42709342PubMed
42696049Evaluation of echocardiographic features and cardiac biomarkers in patients with AA amyloidosis: a retrospective comparative study with patients with al amyloidosis and hypertrophic cardiomyopathy.Rheumatol Int2026https://conductscience.org/library/papers/42696049PubMed
42633047Delayed kidney response in AL amyloidosis: prevalence and clinical significance.Clin Kidney J2026https://conductscience.org/library/papers/42633047PubMed
42597282A rare coexistence of immunoglobulin light chain amyloidosis and POEMS syndrome manifesting as refractory heart failure: a case report and literature review.Front Immunol2026https://conductscience.org/library/papers/42597282PubMed
42566913Limited duration of dexamethasone in newly diagnosed AL amyloidosis: impact on response, toxicity, and survival.Ann Med2026https://conductscience.org/library/papers/42566913PubMed
42559781Cardiac Tamponade From Lymphocytic Constrictive Pericarditis in Primary AL Amyloidosis Without Myocardial Involvement.JACC Case Rep2026https://conductscience.org/library/papers/42559781PubMed
42535167Clinicopathological Characteristics and Prognostic Implications of Periodic Acid-Schiff-Positive Amyloid Deposits in Renal AL Amyloidosis.Kidney Dis (Basel)2026https://conductscience.org/library/papers/42535167PubMed
42459135What's liver got to do with it? Hepatic response and survival in AL amyloidosis.Haematologica2026https://conductscience.org/library/papers/42459135PubMed
42437238Cholestatic Jaundice Without Hepatomegaly as the Initial Manifestation of Hepatic Amyloid Light-Chain (AL) Amyloidosis: A Case of Rapid Multiorgan Failure.Cureus2026https://conductscience.org/library/papers/42437238PubMed
42332218Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.Bone Marrow Transplant2026https://conductscience.org/library/papers/42332218PubMed
42322078Long-Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab-Based Frontline Therapy.Am J Hematol2026https://conductscience.org/library/papers/42322078PubMed
42311430Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases.Hemasphere2026https://conductscience.org/library/papers/42311430PubMed
42258481Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.CA Cancer J Clin2026https://conductscience.org/library/papers/42258481PubMed
42252535Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.Am J Hematol2026https://conductscience.org/library/papers/42252535PubMed
42234146When AL amyloidosis meets the liver: integrating clinical insight and current understanding.Ann Hematol2026https://conductscience.org/library/papers/42234146PubMed
42149416Daratumumab-based therapy in systemic AL amyloidosis including advanced cardiac involvement: a single center study.Int J Hematol2026https://conductscience.org/library/papers/42149416PubMed
41994108Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.Res Sq2026https://conductscience.org/library/papers/41994108PubMed

See all 512 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/16044444

GET https://conductscience.org/api/papers/v1/16044444/cited_by?page=2